Top Ten most popular articles on Pharmafile.com this week
pharmafile | June 23, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â top tenÂ
We’re officially into summer, and the weekend is here. This week saw a number of stories that piqued the attention of our readers. In particular, we finally have resolution on the Luke Miels, who was facing legal action from his former employer AstraZeneca for jumping ship to rival GlaxoSmithKline. After a full decade, Shire finally sees approval of its ADHD treatment Mydayis, and Novartis received European approval for iits biosimilar version of Roche’s blockbuster drug Rituxan.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. GSK’s new President of Global Pharma join date revealed as AZ drops lawsuit
Luke Miels left AZ in January to join GSK as the firm’s President of Global Pharmaceuticals, only to face a lawsuit from his former employer over allegations he breached the terms of his contract. Now, his start date with his new company has been announced.
9. FDA fast-tracks Pfizer and Lilly’s chronic pain drug
Pfizer and Eli Lilly are celebrating the FDA’s decision to grant fast-track designation to their joint venture tanezumab in the treatment of chronic low back pain (CLBP) and pain in osteoarthritis (OA) patients.
8. Immune system attacks the brain in Alzheimer’s, study suggests
New research has identified direct evidence that the body’s immune system attacks the brain in Parkinson’s disease, seemingly confirming a theory of ‘autoimmunity’ which was first posited almost 100 years ago.
7. FlyPharma Conference 2017 – “Collaboration is the key”
The FlyPharma event took place on 6-7 of June, with delegates from airlines mingling with logistics companies, individuals from the pharmaceutical industry and those working in the regulatory industry.
6. Novartis receives positive news in eye drug P3 studies
Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it as effective as its nearest rival but needing fewer doses.
5. Drug that induces tanning could protect against melanoma
Researchers have used small molecules to activate the pigmentation pathway in mice and small samples of human skin, leading to the appearance of darker skin.
4. 10 years later, Shire gains FDA approval for ADHD drug
Shire has revealed that the FDA has approved its long-acting and interestingly named ADHD drug, Mydayis. The approval comes more than 10 years from the first time that the drug was submitted to the FDA in 2006.
3. Novartis receives European biosimilar approval for Roche blockbuster
Sandoz, a division within Novartis, has received European Commission approval for its biosimilar version of Roche’s Rituxan (also known as MabThera).
2. Continuous Manufacturing: Novartis’ experiment in the future of drug production
Continuous manufacturing has long been touted as the future of drug production. Pharmafile approached Novartis for more details about its successes in the area, and the challenges, of developing the new process.
1. FDA locks down import from 3 Indian IPCA facilities
More drama in the Indian pharma sector as the FDA announces it has enforced a ban on the import of drug products manufactured at three sites owned by IPCA Laboratories, preventing them from entering the US.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
